Targeting hippocampal neurons to unlock existing Alzheimer’s drugs

A team of researchers at Kobe Gakuin University in Japan have genetically engineered insulin-fused proteins capable of targeting hippocampal neurons. The innovative technique capitalizes on insulin’s natural tendency to accumulate in the hippocampal neuronal tissue. This new approach could unlock existing treatments for neurodegenerative disorders such as Alzheimer’s disease by allowing existing drugs to be delivered on target.